Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 3 5Phase 1/2 2Phase NA 1Phase 1 1

Status

Unknown 2Recruiting 2

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 1Metastatic HER2 Positive Gastroesophageal Junction Cancer 1

Interventions

pembrolizumab 109Cyclophosphamide 85fludarabine 67Carboplatin 59Injections 58Bevacizumab 52Specimen Handling 42Gemcitabine 41Paclitaxel 40Magnetic Resonance Spectroscopy 40venetoclax 38Nivolumab 38Cisplatin 37Dexamethasone 35Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Oxaliplatin 26Capecitabine 26Pemetrexed 25Fluorouracil 25toripalimab 24abemaciclib 24Irinotecan 24Azacitidine 24Fulvestrant 23Rituximab 21fludarabine phosphate 20durvalumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × XELOX × Clear all
NCT07334431 2026-01-12

Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer

Henan Cancer Hospital

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Stomach Neoplasms

NCT06650332 2024-10-21

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Zhejiang Cancer Hospital

Phase 1/2 Recruiting
90 enrolled
Gastrointestinal

Metastatic HER2 Positive Gastroesophageal Junction Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡